How COVID-19 has changed the role of pharma sales reps

cafead

Administrator
Staff member
  • cafead   Mar 18, 2021 at 11:42: AM
via The demise of the pharmaceutical sales representative has been greatly exaggerated over the years. But in the wake of the COVID-19 pandemic, there is an even greater need to re-examine the rep’s role. How can a field force evolve to deal with current challenges and be future-fit for the way we will be working in the post-pandemic world?

article source
 




First off, big Pharma has to admit that the current model of doing business is antiquated. Managing by objectives and metrics such as calls per day; lunch activity, frequency, speaker programs, tasked tutorials...etc is old Pharma. What value does a rep bring to an office/clinic/hospital other than breakfast, lunch or ice cream will depend on the HCP’s and how they are reimbursed for their medical services provided. Those in an IDN or hospital system are primarily closed off to reps. Unfortunately, with sunshine act and compliance matters, many activities that would bring value are obsolete. Bringing back medical education credits (CE) would be a start to provide value amongst so many other creative ways to interact. The other big elephant in the room is the notion that many new ideas would require a smaller sales force, which means, layoffs from rep to manager to area director to marketing, ops...all the way up.